Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MYRIAD GENETICS INC
Report date September 16, 2026 · Filed September 18, 2026
Section 16 reporting ended · disclosed 2026-09-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 573,363 |
Reported balance
Holding disclosure · report date 2026-09-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 573,363 |
| Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 236,167 |
Reported balance
Holding disclosure · report date 2026-09-16 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 236,167 F1: The shares subject to the performance-based restricted stock units ("PSUs") represent the maximum number of shares that may vest based on the Issuer's achievement of specified stock price milestones. The PSUs will vest upon certification by the Compensation and Human Capital Committee as to 25% of the shares upon the achievement of each of four stock price milestones. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the performance-based restricted stock units ("PSUs") represent the maximum number of shares that may vest based on the Issuer's achievement of specified stock price milestones. The PSUs will vest upon certification by the Compensation and Human Capital Committee as to 25% of the shares upon the achievement of each of four stock price milestones.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 22:05 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 5,000 | $3.94 | $19,680.00 |
DisclosureSEC source: 0002065630-26-000006 · wk-form4_1781301956.xml · nonDerivative · entry 1 Donnelly Brian J · CIK 0002065630 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 573,363 F1 · shares: These shares were acquired under the Issuer's Amended and Restated 2012 Employee Stock Purchase Plan, in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:35 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 55,975 | $4.80 | $268,680.00 |
DisclosureSEC source: 0002065630-26-000004 · wk-form4_1777926939.xml · nonDerivative · entry 1 Donnelly Brian J · CIK 0002065630 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 568,363 F1 · shares: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on May 1, 2026. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 21:05 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 226,804 | $0.00 | $0.00 |
DisclosureSEC source: 0002065630-26-000002 · wk-form4_1773695144.xml · nonDerivative · entry 1 Donnelly Brian J · CIK 0002065630 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 624,338 F1 · shares: Consists of time-based restricted stock units granted pursuant to the Issuer's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:15 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantPerformance-Based Restricted Stock Units · Derivative | 236,167 | $0.00 | $0.00 |
DisclosureSEC source: 0002065630-25-000004 · wk-form4_1746216907.xml · derivative · entry 3 Donnelly Brian J · CIK 0002065630 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,167 Underlying: Common Stock · 236,167 shares Expires not disclosed F3 · derivative.exercise_price: The shares subject to the performance-based restricted stock units ("PSUs") represent the maximum number of shares that may vest based on the Issuer's achievement of specified stock price milestones. The PSUs will vest upon certification by the Compensation and Human Capital Committee as to 25% of the shares upon the achievement of each of four stock price milestones, subject to the reporting person's continued employment or service through the applicable vesting date; provided; however, that no portion of the PSUs may vest earlier than May 1, 2026. F3 · derivative.exercise_date: The shares subject to the performance-based restricted stock units ("PSUs") represent the maximum number of shares that may vest based on the Issuer's achievement of specified stock price milestones. The PSUs will vest upon certification by the Compensation and Human Capital Committee as to 25% of the shares upon the achievement of each of four stock price milestones, subject to the reporting person's continued employment or service through the applicable vesting date; provided; however, that no portion of the PSUs may vest earlier than May 1, 2026. F3 · derivative.expiration_date: The shares subject to the performance-based restricted stock units ("PSUs") represent the maximum number of shares that may vest based on the Issuer's achievement of specified stock price milestones. The PSUs will vest upon certification by the Compensation and Human Capital Committee as to 25% of the shares upon the achievement of each of four stock price milestones, subject to the reporting person's continued employment or service through the applicable vesting date; provided; however, that no portion of the PSUs may vest earlier than May 1, 2026. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:15 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 127,629 | $0.00 | $0.00 |
DisclosureSEC source: 0002065630-25-000004 · wk-form4_1746216907.xml · nonDerivative · entry 2 Donnelly Brian J · CIK 0002065630 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 397,534 F2 · shares: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:15 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 269,905 | $0.00 | $0.00 |
DisclosureSEC source: 0002065630-25-000004 · wk-form4_1746216907.xml · nonDerivative · entry 1 Donnelly Brian J · CIK 0002065630 · Chief Commerical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,905 F1 · shares: Consists of time-based restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.